ANNEXON, INC. Debt Securities, Available-for-sale, Allowance for Credit Loss
ANNEXON, INC. (ANNX) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |